Author: Mark Du Bois

Ziccum participated in the Nordic Life Science Days held in Malmö on 18-19 September 2024. This premier event brought key innovators from across the European life science industry together.

Scientific Director Fabrice Rose: “Attending NLS Days provided a great opportunity to exchange insights with leading professionals in our field. I am pleased with the strong interest in LaminarPace. The dialogues initiated here are promising for future collaborations and advancing the accessibility of mRNA treatments.”

Join Ziccum at Bio-Europe, taking place on November 4-6, 2024 in Stockholm. Please discover how LaminarPace formulation + drying technology is revolutionizing biopharmaceuticals to convert fragile liquid biologics into robust, thermostable, high-yield dry powders with particle engineering.

Meet Ziccum CEO Ann Gidner at the event to explore LaminarPace’s extensive and validated data for mRNA/LNP formulations, see how it solves critical stability challenges, drastically reduces drug costs and unlocks new therapeutic possibilities.

You could book a meeting here: https://ziccum.com/about-us/contact/

Ziccum CEO Ann Gidner shared insights in an interview at BioStock Investing in Life Science: From Seed to Success, held in Stockholm on September 12^th, 2024, discussing the groundbreaking LaminarPace technology that fully unlocks the potential of mRNA.

This innovative technology utilizes mass transfer, not heat, to convert fragile liquid biologics into robust, thermostable, high-yield dry powders, opening the door to entirely new drug delivery options and offering exciting possibilities for therapeutic applications, such as inhalable mRNA—a true game changer for the biopharmaceutical industry.

To learn more, watch the full interview here: Ziccum | INTERVIEW | Investing in Life Science 2024 (youtube.com)

On September 12^th in Stockholm, Ziccum CEO Ann Gidner delivered a compelling presentation at BioStock Investing in Life Science: From Seed to Success, garnering strong interest from life science leaders and investors.

The presentation showcased Ziccum’s innovative LaminarPace technology—a groundbreaking solution for the formulation and drying of delicate liquid biologics. The audience expressed significant interest in Ziccum’s advancements, recognizing the transformative impact LaminarPace could have on future biopharmaceuticals.

Please watch the full presentation here to discover more about LaminarPace and its significant role in addressing stability challenges, reducing production costs and increasing drying yield: https://youtu.be/T_OIl0LHrjw

We are excited to share a new article from Dagens Industri that highlights why Ziccum’s LaminarPace technology is revolutionary for the pharmaceutical industry, and how groundbreaking findings on increased mRNA activity could mark the beginning of a new era in the mRNA sector.

The article discusses how Ziccum has found a solution to one of the pharmaceutical industry’s biggest challenges: effectively drying complex and fragile mRNA, all while offering significant cost reductions. On top of that, new findings reveal that LaminarPace not only preserves mRNA activity but also enhances it for certain formulations. This means that the pharmaceutical industry potentially could create even more effective treatments and overcome dose limitations.

You may read the full article (in Swedish) here: https://www.di.se/bors/aktier/zicc-4004570/investor-relations/

Ziccum CEO Ann Gidner’s presentation at RNA Leaders in San Diego on September 4th, 2024, drew significant attention from key stakeholders in the RNA development community. It addressed a critical challenge in the mRNA field: how to create high-yield, particle engineered, thermostable, and robust drug forms to unlock the full potential of mRNA.

CEO Ann Gidner: “We had a well-placed speaker slot and got good attention, with new dialogues regarding interesting applications. It’s always rewarding to reconnect with key contacts and meet new, promising collaborators as we strive to contribute to the next era of RNA innovation. Thank you to everyone who made this event a success.”

Scientific Director Fabrice Rose: “It was a valuable experience to attend this event and stay updated on the latest developments in the rapidly evolving RNA field. I am pleased with the strong interest in our technology and our latest mRNA findings with LaminarPace.”

On August 29th, 2024, Ziccum participated in the Future of Swedish & Danish Life Science event in Lund. This well-attended gathering brought together key players from the Swedish and Danish life science sectors, promoting collaboration and showcasing the latest advancements.

COO Xavier Turon: “It was very nice to connect with key stakeholders from the Swedish and Danish life science sectors, fostering partnerships and sharing the latest innovations. During the event, we engaged with numerous established contacts and raised awareness about Ziccum’s unique LaminarPace™ technology.”

Ziccum attended the New Updates in Drug Formulation & Bioavailability event in Copenhagen on August 28th, 2024. This event provides a dynamic platform for bringing together R&D professionals and pharma industry representatives, discussing industry developments in drug formulation.

Scientific Director Fabrice Rose: “It was a pleasure to explore new developments in pharmaceutical formulations and share insights with leaders in the pharma industry. We were thrilled by the strong interest in our unique LaminarPace technology and its potential to open a new era in drug formulation and delivery systems.”

Ziccum’s unique LaminarPace technology transforms delicate liquid biotherapeutics into robust, thermostable, and high-yield dry powders without exposing them to extreme temperatures, stress, or degradation. This innovative approach ensures the preservation, and even enhancement, of mRNA drug activity in dried materials.

Join Ziccum at the Future of Swedish & Danish Life Science event in Lund on August 29^th. Meet with COO Xavier Turon to discover how LaminarPace is setting new standards in biotherapeutic formulation and learn more about its potential to revolutionize mRNA-based treatments.

Book a meeting here: https://ziccum.com/about-us/contact/